AI and ML Enhance ECG Interpretation

By Michael Awood

September 22, 2023

We’ve shown how AI and ML help diagnose and manage heart problems. New research has recently shown that a new ML model can improve ECG data interpretation, reducing misdiagnosis and optimizing patient monitoring data.

A further step is to look at monitoring and early disease detection while patients are being monitored within the home space. This is something our recent insight article has touched on.

By using traditional signal processing and ML, this model can overcome challenges caused by noisy data. They evaluated it using real-world single-lead ECG data from acutely ill patients receiving care at home as part of a ‘home hospital’ program. The model showed excellent performance, with a sensitivity of 98%, a specificity of 100%, an accuracy of 98%, a positive predictive value of 100%, and a negative predictive value of 93%.

It was effective in interpreting telemetry feeds for acutely ill patients. The current systems can detect atrial fibrillation with 92% accuracy and paroxysmal supraventricular tachycardia with 93% accuracy. However, the new ML algorithm could enhance arrhythmia identification.

The ML model can monitor chronically ill patients during medication changes or diagnose hidden arrhythmia. It could form the basis of a system that consistently monitors cardiac health through arrhythmia detection.

The study evaluated a single-lead ECG hybrid ML algorithm using data from acutely ill patients within a ‘home hospital’ programme. It shows the potential of AI and ML to enhance healthcare delivery and patient outcomes, particularly in cardiology. Investigating the impact of long-term arrhythmia burden on health outcomes is crucial for future research.

Reference url

Recent Posts

Joint Scientific Consultation EU
Joint Scientific Consultation EU Strategies for Medical Device Companies

By João L. Carapinha

June 19, 2026

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...
EU Joint Clinical Assessment
Insights on EU Joint Clinical Assessment for High-Risk Medical Devices

By João L. Carapinha

June 19, 2026

EU Joint Clinical Assessment is a distinct, harmonised process that operates separately from CE marking. It produces comparative clinical evidence on selected high-risk devices to support more consistent national reimbursement decisions across EU member states. Insights from the
LesionAttn Skin Cancer AI
LesionAttn Skin Cancer AI Enhances Fairness in Dermatological Diagnostics

By João L. Carapinha

June 19, 2026

LesionAttn Skin Cancer AI tackles a critical flaw in current skin cancer detection tools: models that unconsciously rely on background skin features differing between men and women, producing unequal accuracy across genders. By steering neural networks to focus on the actual lesion instead of the...